Roche’s Ophthalmic Bi-Specific Faricimab Still A DME Contender
Data In Wet AMD Still Awaited
Initial data show non-inferiority to Eylea in diabetic macular edema with reduced frequency dosing but not superiority. Even so, market dynamics suggest it could still carve out blockbuster sales.
